INTRODUCTION
============

*Pneumocystis* pneumonia (PCP) is a well-known opportunistic infection that affects patients infected with human immunodeficiency virus (HIV) \[[@b1-kjim-2015-340]\]. PCP, the incidence of which continues to increase, also occurs in immunocompromised patients without HIV, such as those with hematological malignancies or solid tumors; those who have undergone organ transplantation; and those receiving immunosuppressants, including corticosteroids \[[@b2-kjim-2015-340]-[@b4-kjim-2015-340]\]. *Pneumocystis jirovecii* may be present in the respiratory tracts of patients without clinical pneumonia. *P. jirovecii* polymerase chain reaction (PCR) positivity could reflect PCR contamination, colonization, or transient carriage of a very small number of *P. jirovecii* organisms, which has been defined as *Pneumocystis* colonization \[[@b5-kjim-2015-340]\].

In immunocompromised patients without HIV, PCP progresses rapidly and causes severe respiratory failure. However, it is often difficult to diagnose. Standard microscopic examinations of sputum or bronchial specimens for *P. jirovecii* organisms have low sensitivity due to the low bacterial burden, and although lung biopsy can be confirmative, it is quite invasive \[[@b6-kjim-2015-340],[@b7-kjim-2015-340]\]. Moreover, the rate of colonization is high in these patients. A recent study documented *Pneumocystis* colonization in induced sputum from 16% of patients with various autoimmune diseases \[[@b8-kjim-2015-340]\]. The molecular detection tool *P. jirovecii* PCR provides a higher degree of sensitivity than do standard methods and can be useful for the clinical diagnosis of PCP \[[@b9-kjim-2015-340]\]. However, its use is limited by *P. jirovecii* colonization, resulting in lower specificity. The clinical value of *P. jirovecii* PCR in diagnosing PCP in patients with systemic diseases has not been defined clearly.

The aim of this study was to evaluate the prevalence of *P. jirovecii* PCR positivity in respiratory samples from immunocompromised patients without HIV who underwent bronchoscopy due to suspected respiratory infection. Furthermore, we attempted to determine the risk of PCP development in these patients by comparing the treatment group (patients diagnosed with PCP) with the non-treatment group (those with suspected colonization).

METHODS
=======

We collected and analyzed the results of *P. jirovecii* PCR performed on bronchial washing fluid or bronchoalveolar lavage fluid (BALF) from adult immunocompromised patients without HIV who were suspected of having respiratory infection at a 1,200-bed tertiary university teaching hospital between May 2009 and September 2012. Medical records of the patients with positive *P. jirovecii* PCR results were reviewed retrospectively. The study was approved by the Institutional Review Board of Seoul St. Mary's Hospital, which permitted evaluation and publishing of information from the patients' records. The requirement for informed consent was waived because of the retrospective nature of the study.

Definite PCP is diagnosed in the presence of a compatible clinical presentation of PCP and a positive immunofluorescent test in BALF \[[@b1-kjim-2015-340],[@b10-kjim-2015-340]\]. In this study, we defined the presence of PCP as *P. jirovecii* PCR positivity and treatment for PCP based on respiratory symptoms and the detection of new pulmonary infiltrates on chest radiography or computed tomography. Patients with PCP were treated with trimethoprim-sulfamethoxazole (TMP-SMX) for 21 days; treatment with other anti-infective agents was withheld, except for patients with coinfections. Co-infected patients were additionally treated with appropriate empirical antibiotics, voriconazole, amphotericin, or ganciclovir, according to the coinfection diagnosed. Adjuvant corticosteroid therapy was administered to patients with partial pressure of arterial oxygen (PaO~2~) values \< 60 mmHg, as in the recommended regimen \[[@b11-kjim-2015-340]\]. Patients without PCP (non-PCP group) were defined as *P. jirovecii* PCR-positive patients who did not require treatment for PCP, suggesting colonization or subclinical infection, rather than PCP.

The baseline clinical data included demographic characteristics, presence of underlying disease, previous use of medications (steroids and other immunosuppressants), and chemotherapy in the previous month; bronchoscopy results, including those from bronchoalveolar lavage, transbronchial lung biopsy (TBLB), and evaluation with special stains (e.g., methenamine silver or Giemsa); laboratory findings, such as complete blood count and blood chemistry; and symptoms, pneumonia severity index (PSI), and radiological findings at the time of *P. jirovecii* PCR testing.

We investigated the clinical outcomes of the two groups regarding the decision to treat (or not to treat) PCP and in-hospital mortality.

We defined improvement as clinical recovery and discharge within 1 month after treatment. Causes of death were divided into four categories: acute respiratory distress syndrome (ARDS), sepsis, multiorgan failure, and cardiac arrest. We used the Berlin definition to diagnose ARDS \[[@b12-kjim-2015-340]\]. Sepsis was defined as the presence (probable or documented) of infection together with systemic manifestations of infection \[[@b13-kjim-2015-340]\]. Organ dysfunction was defined according to Marshall et al. \[[@b14-kjim-2015-340]\]. Cardiac arrest was defined as the cessation of cardiac mechanical activity with loss of effective circulation, as determined by the absence of a palpable central pulse \[[@b15-kjim-2015-340]\].

*P. jirovecii* polymerase chain reaction
----------------------------------------

A PCR method for the detection of *P. jirovecii* DNA was developed at our institution. In detail, DNA was extracted from bronchial washing fluid or BALF using a QIAamp mini kit (Qiagen, Hilden, Germany), and the pneumocystis mitochondrial region (mtLSU rRNA) was amplified using nested PCR \[[@b16-kjim-2015-340],[@b17-kjim-2015-340]\]. In the two amplification rounds, external and internal primers made by our institute were used, and Taq DNA polymerase (Promega, Southampton, UK) was used throughout the study. Each round comprised 40 cycles of amplification. The amplification products were visualized using ultraviolet light following agarose gel electrophoresis and staining with ethidium bromide. Extreme care was taken to eliminate the possibility of false-positive reactions caused by contamination. All experiments were performed at least twice.

Statistical analysis
--------------------

Continuous variables were presented as mean ± standard error of the mean and analyzed using two independent-sample *t* tests. Categorical variables were presented as frequencies and percentages, and analyzed using Pearson chi-square test or Fisher exact test for discrete variables. Univariate and multivariate logistic regression analyses were performed to analyze the risk factors for clinical PCP development, with calculation of odds ratios (ORs), 95% confidence intervals (CIs), and *p* values. All tests were two sided and *p* \< 0.05 were considered to be statistically significant. All analyses were performed with the SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

Baseline demographics of the study population
---------------------------------------------

*P. jirovecii* PCR testing of bronchial washing fluid or BALF yielded positive results for 169 of 1,233 patients (13.7%). PCP was diagnosed in 90 (53.3%) of these patients. Among *P. jirovecii* PCR-positive patients, PCP was present in larger percentages of patients with hematological disease, those who had undergone solid organ transplantation, and those with autoimmune disease ([Fig. 1](#f1-kjim-2015-340){ref-type="fig"}).

Baseline data for the PCP and non-PCP groups are summarized in [Table 1](#t1-kjim-2015-340){ref-type="table"}. The PCP group was significantly younger than the non-PCP group (55.3 ± 1.7 years vs. 61.1 ± 1.9 years, *p* = 0.02). Compared with the non-PCP group, the PCP group had significantly higher percentages of hematological malignancies (42% vs. 28%, *p* \< 0.001), solid tumors (30% vs. 20%, *p* \< 0.001), and solid organ transplant recipients (12% vs. 4%, *p* \< 0.001). No significant difference in previous steroid treatment, use of immunosuppressants (e.g., cyclosporine, tacrolimus), or methotrexate use or chemotherapy was observed between groups.

Comparison of clinical manifestations in PCP and non-PCP patients with *P. jirovecii* PCR positivity
----------------------------------------------------------------------------------------------------

Laboratory data from the two groups are shown in [Table 2](#t2-kjim-2015-340){ref-type="table"}. Serum C-reactive protein levels were significantly higher in the PCP group than in the non-PCP group (11.4 ± 0.9 mg/dL vs. 8 ± 0.8 mg/dL, *p* = 0.01). Serum albumin levels were significantly lower in the PCP group (2.9 ± 0.1 g/dL vs. 3.2 ± 0.1 g/dL, *p* \< 0.001). No significant difference in the white blood cell count, serum level of lactate dehydrogenase, PaO~2~, or PSI was observed between the groups. Regarding symptoms, the incidence of dyspnea was significantly higher in the PCP group than in the non-PCP group (62% vs. 30%, *p* \< 0.001). Radiological findings revealed a higher incidence of ground-glass opacities in the bilateral lungs in the PCP group (80% vs. 63%, *p* = 0.02).

Comparison of clinical outcomes in PCP and non-PCP patients with *P. jirovecii* PCR positivity
----------------------------------------------------------------------------------------------

Clinical outcomes of the two groups are shown in [Table 3](#t3-kjim-2015-340){ref-type="table"}. Fifty-six patients (62%) in the PCP group improved with TMP-SMX treatment, and 66 of 79 patients (84%) in the non-PCP group recovered in their clinical course due to other following treatments; supportive care (6/66), antibiotics (48/66), antituberculosis medication (3/66), antifungal (1/66), others (steroid, tamiflu, etc.; 8/66).

The fatality rate was higher in the PCP group than in the non-PCP group (38% vs. 16%, *p* = 0.002). In the PCP group (n = 90), 34 patients died of ARDS, sepsis, or multiorgan failure. Among them, two patients died due to exacerbation of PCP despite treatment.

In the non-PCP group, 66 patients improved following various treatments: supportive care (6/66), antibiotics (48/66), antituberculosis medication (3/66), antifungals (1/66), and others (e.g., steroids, tamiflu; 8/66). No patient in this group died due to PCP worsening.

Predictive parameters for PCP among *P. jirovecii* PCR-positive patients
------------------------------------------------------------------------

In [Table 4](#t4-kjim-2015-340){ref-type="table"}, multivariate logistic regression analysis revealed that the independent risk factors for PCP diagnosis in *P. jirovecii* PCR-positive patients were underlying conditions, such as hematological malignancies, solid tumors, and solid organ transplant receipt (OR, 8.61; 95% CI, 3.08 to 24.09; *p* \< 0.001); dyspnea (OR, 4.59; 95% CI, 1.95 to 10.76; *p* \< 0.001); age \> 60 years (OR, 1.03; 95% CI, 1.0 to 1.06; *p* = 0.02); and albumin \< 2.9 g/dL (OR, 3.08; 95% CI, 1.34 to 7.08; *p* = 0.01).

DISCUSSION
==========

In the current study, we divided the *P. jirovecii* PCR-positive population into two groups---patients with clinical diagnoses of PCP who received TMP-SMX treatment, and those diagnosed simply with colonization---and compared the two groups to evaluate the risk factors for PCP. The results showed that PCP was more common in *P. jirovecii* PCR-positive patients aged \< 60 years; those with hematological malignancies and solid tumors; those who were solid organ transplant recipients; those with low albumin levels; and those with symptoms of dyspnea. Moreover, colonization was detected in a considerable percentage of *P. jirovecii* PCR-positive immunocompromised patients, indicating that they did not require treatment.

The diagnosis of PCP in clinical practice is challenging. First, the diagnostic yields of direct staining and lung biopsy are low, ranging from 38% to 53% \[[@b6-kjim-2015-340],[@b7-kjim-2015-340]\]; values are lower for immunocompromised patients without HIV than for patients with HIV. Second, some methods, such as TBLB, are invasive and often inaccessible in a clinical setting. Lastly, the symptoms and radiological findings at the time of PCP development are frequently nonspecific and ambiguous. Recently, the *P. jirovecii* PCR method has helped to improve the diagnostic sensitivity of PCP diagnosis from BALF and induced sputum. However, the differentiation of infection and colonization in the PCR-based diagnosis of PCP can be difficult, particularly in patients without HIV \[[@b18-kjim-2015-340]\]. The extent of colonization has been debated, with different rates of *P. jirovecii* carriage reported. Nevez et al. \[[@b19-kjim-2015-340]\] reported that 20% of 169 HIV-negative patients with moderate or severe immunosuppression showed *P. jirovecii* positivity according to nested PCR; none of these patients developed PCP. In the current study, 37% of patients with hematological malignancies, 37% of those with solid tumors, 21% of solid organ transplant recipients, 56% of patients with autoimmune diseases, and 81% of patients with other diseases had *P. jirovecii* colonization. Most (83.5%, n = 66) patients in the non-PCP group, who were *P. jirovecii* PCR-positive according to analysis of bronchoscopic specimens, recovered without treatment of PCP, indicating that they were colonized or had subclinical infection. This finding suggests that a fair number of patients with *P. jirovecii* PCR positivity do not need to be treated, despite their low immune status. On the other hand, *P. jirovecii* colonization has several clinical implications. It may increase the risk of acute PCP in susceptible hosts, or result in the transmission of *P. jirovecii* to others \[[@b16-kjim-2015-340],[@b20-kjim-2015-340]\]. Nevertheless, the duration of colonization before the development of PCP and the efficacy of treating colonization to prevent disease are unknown \[[@b21-kjim-2015-340]\].

In our study, we attempted to determine the predictive factors of PCP among *P. jirovecii*-positive patients by comparing the PCP and non-PCP groups. The PCP group contained significantly larger percentages of patients with hematological malignancies, those with solid tumors, and solid organ transplant recipients among various underlying immunocompromising diseases. The higher incidence of PCP among these patients might be due primarily to a higher net state of immunosuppression caused by the underlying disease and the intensity of chemotherapy or immunosuppressant use in these patients \[[@b22-kjim-2015-340]\].

Intriguingly, the current study showed that patients in the PCP group were significantly younger than those in the non-PCP group. Previous reports showed an association between age \> 60 years and pulmonary *Pneumocystis* colonization, especially in patients with rheumatoid arthritis \[[@b23-kjim-2015-340],[@b24-kjim-2015-340]\]. Advanced age itself may compromise the immune system, leads to increased *Pneumocystis* colonization. This hypothesis should be tested in future studies.

Dyspnea symptoms were significantly more common in the PCP group than in the non-PCP group. However, interestingly, PaO~2~ did not differ between groups. *P. jirovecii* PCR-positive patients with subjective symptoms of dyspnea despite no evidence of hypoxia should be evaluated carefully for evidence of PCP. Significant hypoalbuminemia, suggesting compromised nutritional status, was noted in the PCP group compared with the non-PCP group. Hypoalbuminemia has been reported as a poor prognostic factor for PCP \[[@b25-kjim-2015-340]\].

Regarding mortality, whereas 34 patients (38%) in the PCP group died despite treatment, 66 patients (84%) in the non-PCP group improved without treatment of PCP. In the clinical PCP group, the main causes of death were ARDS, multiorgan failure, sepsis, and cardiac arrest. Some patients may have died due to conditions other than PCP, whereas others may have died due to refractoriness to PCP therapy. In contrast, in the non-PCP group, most patients survived with adequate treatment other than PCP therapy. This finding suggests a considerable incidence of colonization in patients with *P. jirovecii* PCR positivity, despite their significant immunodeficient status.

The limitations of this study were its retrospective nature and the use of a clinical diagnosis as the gold standard for PCP, as opposed to the performance of lung biopsy in all patients. However, lung biopsy is quite invasive and often extremely risky in these patients. In addition, some studies have failed to show benefits in terms of PCP diagnosis \[[@b26-kjim-2015-340]\].

Another limitation was that we used conventional PCR methods instead of quantitative real-time PCR assays, which have been reported to be more reliable for the diagnosis of PCP \[[@b27-kjim-2015-340],[@b28-kjim-2015-340]\]. Quantitative real-time PCR assays, along with the use of serum markers such as ß-D glucan, enable differentiation between PCP and *Pneumocystis* colonization \[[@b27-kjim-2015-340]-[@b30-kjim-2015-340]\]. However, these assays are costly and their cut-off values are not standardized; therefore, their application in clinical practice remains limited.

KEY MESSAGE
===========

1\. Not all *Pneumocystis jirovecii* polymerase chain reaction (PCR)-positive patients need to be treated for Pneumocystis pneumonia (PCP), considering their low immune status.

2\. In cases of *P. jirovecii* PCR positivity, the risk of definitive PCP is higher in patients aged \< 60 years, those with hematological malignancies or solid tumors, solid organ transplant recipients, patients with low albumin levels (\< 2.9 g/dL), and those with symptoms of dyspnea.

3\. Treatment of PCP should be considered in these patients.
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![Analysis of underlying diseases among positive *Pneumocystis jirovecii* polymerase chain reaction (PCR) patients.](kjim-2015-340f1){#f1-kjim-2015-340}

###### 

Baseline characteristics

  Characteristic                                                      PCP (n = 90)   Non-PCP (n = 79)   *p* value
  ------------------------------------------------------------------- -------------- ------------------ -----------
  Age, yr                                                             55.3 ± 1.7     61.1 ± 1.9         0.020
  Male sex                                                            56 (62)        52 (66)            0.630
  Underlying disease                                                                                    \< 0.001
   Hematological malignancies                                         38 (42)        22 (28)            
   Solid tumors                                                       27 (30)        16 (20)            
   Solid organ transplant recipients                                  11 (12)        3 (4)              
   Autoimmune disease                                                 8 (9)          10 (13)            
   Others^[a](#tfn1-kjim-2015-340){ref-type="table-fn"}^              5 (6)          26 (33)            
   None                                                               1 (1)          2 (2)              
  Previous steroid treatment                                          32 (36)        18 (23)            0.070
  Immunosuppressants^[b](#tfn2-kjim-2015-340){ref-type="table-fn"}^   34 (38)        20 (25)            0.080
  Chemotherapy within 1 month                                         21 (23)        11 (14)            0.120

Values are presented as mean ± SEM or number (%).

PCP, *Pneumocystis* pneumonia.

Others include liver cirrhosis, pulmonary tuberculosis, end stage renal disease, interstitial lung disease, and chronic obstructive lung disease.

Immunosuppressants include cyclosporine, tacrolimus, and methotrexate.

###### 

Comparison of clinical manifestations between PCP and non-PCP patients with positive *Pneumocystis jirovecii* polymerase chain reaction

  Variable                   PCP (n = 90)      Non-PCP (n = 79)   *p* value
  -------------------------- ----------------- ------------------ -----------
  Lab data                                                        
   WBC, /mm^3^               9,066.4 ± 641     8,240.1 ± 693.7    0.380
   Lymphocyte, /mm^3^        1,352.6 ± 405.7   1,180.1 ± 118.8    0.740
   ANC, /mm^3^               7,224.9 ± 521.4   6,124.1 ± 562.3    0.150
   LDH, U/L                  1,027.3 ± 165.5   663.7 ± 53.9       0.050
   CRP, mg/dL                11.4 ± 0.9        8 ± 0.8            0.010
   Albumin, g/dL             2.9 ± 0.1         3.2 ± 0.1          \< 0.001
   PaO~2~, mmHg              76.8 ± 2.2        76.5 ± 2.8         0.940
  Symptoms                                                        
   Fever                     57 (63)           40 (51)            0.100
   Cough                     33 (37)           31 (39)            0.730
   Sputum                    30 (33)           28 (35)            0.770
   Dyspnea                   56 (62)           24 (30)            \< 0.001
  Pneumonia severity index   102.1 ± 3.4       96.6 ± 4           0.300
  Radiology                                                       
   Bilateral lung GGO        72 (80)           50 (63)            0.020

Values are presented as mean ± SEM or number (%).

PCP, *Pneumocystis* pneumonia; WBC, white blood cell; ANC, absolute neutrophil count; LDH, lactate dehydrogenase; CRP, C-reactive protein; PaO~2~, partial pressure of arterial oxygen; GGO, ground glass opacity.

###### 

Clinical outcome between PCP and non-PCP patients with positive *Pneumocystis jirovecii* polymerase chain reaction

  Variable               PCP (n = 90)   Non-PCP (n = 79)                                         *p* value
  ---------------------- -------------- -------------------------------------------------------- -----------
  Improved               56 (62)        66^[a](#tfn3-kjim-2015-340){ref-type="table-fn"}^ (84)   0.002
  Death                  34 (38)        13 (16)                                                  
  Cause of death                                                                                 
   ARDS                  12/34          3/13                                                     
   Sepsis                5/34           2/13                                                     
   Multiorgan failure    12/34          5/13                                                     
   Cardiac arrest        3/34           3/13                                                     
  Death related to PCP   2 (2)          0                                                        

Values are presented as number (%).

PCP, *Pneumocystis* pneumonia; ARDS, acute respiratory distress syndrome.

Improvement in the non-PCP group (n = 66) is due to the following; supportive care (6/66), antibiotics (48/66), anti-tuberculosis medication (3/66), anti-fungal (1/66), others (steroid, tamiflu, etc.; 8/66).

###### 

Multivariate regression analysis for the risk factor of *Pneumocystis* pneumonia development among positive *Pneumocystis jirovecii* polymerase chain reaction patients

  Variable                                         OR     95% CI        *p* value
  ------------------------------------------------ ------ ------------- -----------
  Hematologic malignancies, solid tumors, or SOT   8.61   3.08--24.09   \< 0.001
  Dyspnea                                          4.59   1.95--10.76   \< 0.001
  Age \< 60 yr                                     1.03   1.00--1.06    0.020
  Albumin \< 2.9 g/dL                              3.08   1.34--7.08    0.010

OR, odds ratio; CI, confidence interval; SOT, solid organ transplantation.
